NCT03633630View on ClinicalTrials.gov

Amla on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

October 30, 2021

Study Completion Date

March 30, 2022

Conditions
Metabolic Syndrome
Interventions
DRUG

Amla

Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days

DRUG

Placebo

Capsules of 500 mg two times per day before breakfast and dinner a total dose of 1000 mg per day. During 90 days

Trial Locations (1)

44340

Institute of Experimental and Clinical Therapeutics, Guadalajara

All Listed Sponsors
lead

University of Guadalajara

OTHER

NCT03633630 - Amla on Metabolic Syndrome, Insulin Sensitivity and Insulin Secretion | Biotech Hunter | Biotech Hunter